Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model

Melanoma is a recalcitrant disease. The present study used a patient-derived orthotopic xenograft (PDOX) model of melanoma to test sensitivity to three molecularly-targeted drugs and one standard chemotherapeutic. A BRAF-V600E-mutant melanoma obtained from the right chest wall of a patient was grown...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawaguchi, Kei, Murakami, Takashi, Chmielowski, Bartosz, Igarashi, Kentaro, Kiyuna, Tasuku, Unno, Michiaki, Nelson, Scott D., Russell, Tara A., Dry, Sarah M., Li, Yunfeng, Eilber, Fritz C., Hoffman, Robert M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342117/
https://www.ncbi.nlm.nih.gov/pubmed/27690220
http://dx.doi.org/10.18632/oncotarget.12328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342117/
https://www.ncbi.nlm.nih.gov/pubmed/27690220
http://dx.doi.org/10.18632/oncotarget.12328

Ejemplares similares